Hanmi Pharm. Co., Ltd. (한미약품(주))
KOSPI Stock Code: 128940 | DART Corp Code: 00828497
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | Hanmi Pharm. Co., Ltd. |
|---|---|
| Korean legal name | 한미약품(주) |
| Alternate names | 한미약품 |
| Market | KOSPI |
| Stock Code | 128940 |
| DART Corp Code | 00828497 |
| CEO | 황상연 |
| Business Registration No. | 1248700613 |
| Corporate Registration No. | 1348110197550 |
| Established Date | 2010-07-05 |
| Fiscal Month | 12 |
| KSIC Industry Code | 21212 |
| Address (KO) | 경기도 화성시 팔탄면 무하로 214 |
| Homepage | N/A |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001130 |
| verified_at | 2026-11-01T02:25:50.561Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001130
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 1,547,531,098,763 | KRW 1,495,501,575,568 |
| Operating Income (영업이익) | KRW 257,799,090,185 | KRW 216,186,188,006 |
| Net Income (당기순이익) | KRW 187,135,533,539 | KRW 140,431,062,099 |
| Total Assets (자산총계) | KRW 2,137,597,680,857 | KRW 2,020,840,493,653 |
| Total Liabilities (부채총계) | KRW 714,744,458,123 | KRW 780,088,902,015 |
| Total Equity (자본총계) | KRW 1,422,853,222,734 | KRW 1,240,751,591,638 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-10-30 | 20261030800861 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 한미약품 |
2026-10-30 | 20261030800002 | Material Business Matters Related to Investment Decisions (파브리병 치료제(LAGLA) 기술이전 계약 체결) | 투자판단관련주요경영사항 (파브리병 치료제(LAGLA) 기술이전 계약 체결) | 한미약품 |
2026-10-27 | 20261027800662 | Retirement of Stocks | 주식소각결정 | 한미약품 |
2026-10-27 | 20261027800461 | Report on Business Performance according to Consolidated Financial Statements (Fair Disclosure) | 연결재무제표기준영업(잠정)실적(공정공시) | 한미약품 |
2026-10-16 | 20261016800703 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 한미약품 |
2026-10-16 | 20261016800700 | Prior Notice on Disclosure of Final Earnings | 결산실적공시예고(안내공시) | 한미약품 |
2026-10-07 | 20261007800667 | Material Business Matters Related to Investment Decisions (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인) | 투자판단관련주요경영사항 (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인) | 한미약품 |
2026-10-06 | 20261006000230 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 국민연금공단 |
2026-10-02 | 20261002000501 | Report on significant holdings of stocks, etc. (Short form) | 주식등의대량보유상황보고서(약식) | 국민연금공단 |
2026-09-29 | 20260929800978 | Material Business Matters Related to Investment Decisions | 투자판단관련주요경영사항 | 한미약품 |
2026-09-29 | 20260929000668 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 한미사이언스 |
2026-09-29 | 20260929000085 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 국민연금공단 |
2026-09-08 | 20260908800596 | Organization of Investor Relations Event | 기업설명회(IR)개최(안내공시) | 한미약품 |
2026-09-08 | 20260908800550 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 한미약품 |
2026-09-08 | 20260908000370 | Report on significant holdings of stocks, etc. (General) | 주식등의대량보유상황보고서(일반) | 한미사이언스 |
2026-08-28 | 20260828800615 | Report on Shares Change of Largest Shareholders | 최대주주등소유주식변동신고서 | 한미약품 |
2026-08-26 | 20260826800466 | [Corrected description]Material Business Matters Related to Investment Decisions (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결) | [기재정정]투자판단관련주요경영사항 (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결) | 한미약품 |
2026-08-24 | 20260824800144 | Material Business Matters Related to Investment Decisions | 투자판단관련주요경영사항 | 한미약품 |
2026-08-21 | 20260821800930 | [Corrected description]Material Business Matters Related to Investment Decisions | [기재정정]투자판단관련주요경영사항 | 한미약품 |
2026-08-21 | 20260821800876 | [Corrected description]Material Business Matters Related to Investment Decisions | [기재정정]투자판단관련주요경영사항 | 한미약품 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320001130 | verified_at: 2026-11-01T02:25:50.561Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.